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Abstract
Tasmanian devils (Sarcophilus harrisii) are on the verge of extinction due to a transmissible cancer, devil facial tumour
disease (DFTD). This tumour is an allograft that is transmitted between individuals without immune recognition of the
tumour cells. The mechanism to explain this lack of immune recognition and acceptance is not well understood. It has been
hypothesized that lack of genetic diversity at the Major Histocompatibility Complex (MHC) allowed the tumour cells to grow
in genetically similar hosts without evoking an immune response to alloantigens. We conducted mixed lymphocyte
reactions and skin grafts to measure functional MHC diversity in the Tasmanian devil population. The limited MHC diversity
was sufficient to produce measurable mixed lymphocyte reactions. There was a wide range of responses, from low or no
reaction to relatively strong responses. The highest responses occurred when lymphocytes from devils from the east of
Tasmania were mixed with lymphocytes from devils from the west of Tasmania. All of the five successful skin allografts were
rejected within 14 days after surgery, even though little or no MHC I and II mismatches were found. Extensive T-cell
infiltration characterised the immune rejection. We conclude that Tasmanian devils are capable of allogeneic rejection.
Consequently, a lack of functional allorecognition mechanisms in the devil population does not explain the transmission of
a contagious cancer.
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Introduction
Devil facial tumour disease (DFTD) is a transmissible Schwanncell
cancer of Tasmanian devils (Sarcophilus harrisii) [1,2,3]. The cancer
cells are passed from animal to animal during the process of biting,
which most frequently occurs on the head and neck. Metastases to
distant organs are common and affected devils die within months
after tumours become apparent [2,4]. This disease was noted in 1996
in the far northeast of Tasmania, and has since spread to over half of
the devil’s range [5,6]. The far northwestern areas of Tasmania still
remain disease free, although it is predicted that DFTD will affect all
devil habitat within the decade. It is possible that extinction of the
species will occur within 20 years [5].
Despite being a cell allograft, DFTD tumours do not evoke an
immune response [7], and there is no evidence of lymphocyte
infiltration into the tumour masses [8]. In vertebrates, organ, tissue
or cell transplants are rejected by the immune system, unless the
recipient is severely immunocompromised or both recipient and
donor share identical Major Histocompatibility Complex (MHC)
genes (e.g. homozygous twins) [9]. MHC genes were originally
identified in mammalian cells, encoding specialised glycoproteins
expressed on the cell surface of almost all nucleated cells. These
genes were first related to foreign tissue (allograft) transplantation,
but are now known to be essential in the immune recognition of
pathogens and tumour cells [10,11]. There are two main MHC
subgroups that have different immunological functions, MHC I
and MHC II. MHC I molecules are composed of a polymorphic
a-chain associated with a non-polymorphic b2-microglobulin. Its
role is to present intracellular antigens to CD8+ T-cells. These
molecules are present on all nucleated cells. MHC II molecules are
composed of a polymorphic a-chain attached to a polymorphic b-
chain, and present extracellular antigens to CD4+ T-cells. Under
normal conditions, MHC II is only located on the cell surface of
professional antigen presenting cells, such as dendritic cells and
macrophages (reviewed in [12,13]). Tasmanian devils have a
competent immune system [14,15], but the devil population has
been through genetic bottlenecks and lacks MHC diversity
[16,17].
MHC molecules regulate the immunological mechanisms of
tissue graft rejection and provoke vigorous T-cell responses against
incompatible cells [18,19]. Different effector processes may reject
the allografts, but the main mediators are CD8+ T-cells and CD4+
T-cells. Allopeptides presented to CD8+ T-cells by MHC I
molecules stimulate the differentiation of cytotoxic T-cells, which
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presented by MHC II molecules activate helper T-cells, which
differentiate and produce cytokines that damage the tissue graft.
Allograft rejection mediated by CD4+ and CD8+ T cells is
deemed acute rejection, as it can usually occur within eight to 12
days after the transplant. This form of rejection is primarily due to
mismatching of MHC loci [20,21].
A predictive in vitro test for T-cell recognition of allogeneic
MHC molecules is the mixed lymphocyte reaction (MLR) [22].
This experiment has been used in clinical analyses of allogeneic
impact of MHC I and II mismatches between live donors (e.g.
kidney donors) and recipients. Donors with poor MLR responses
against the recipient have lower incidence of graft rejection
[23,24]. MLR experiments can be performed with cultured
lymphocytes from both donor and recipient and the resultant
proliferation will correspond to differences in the MHC alleles of
both individuals (two-way MLR). By inactivating the mononuclear
cells from the donor (by X-irradiation or chemical mitotic
inhibition), only the recipient response is evaluated (one-way
MLR).
Skin grafting between unrelated individuals has been performed
to test MHC disparity in a wild mammal, the cheetah (Acynonyx
jubatus). Captive cheetahs were unable to quickly recognize
alloantigens as foreign and reject the skin grafts [25]. More
recently, wild-living Namibian cheetahs were shown to have low
levels of MHC variation, although this did not appear to impair
their immune response against infectious diseases [26,27]. To date,
a lack of MHC diversity has been the primary reason given for the
lack of rejection of allograft tumours by Tasmanian devils. It has
been proposed that devils have a similar range of MHC antigens
as the tumours [16,17], and therefore do not see the tumours as
foreign. Acceptance, or delayed rejection, of skin allografts would
help to confirm the theory that impoverished MHC diversity is
responsible for a lack of tumour allograft recognition [28,29]. To
determine whether this limited MHC diversity is sufficiently low to
permit allograft transplantation, we characterised levels of
functional MHC variation by two-way MLR and skin grafts
experiments.
Materials and Methods
Ethics statement
All experiments describing the use of animals were undertaken
with approval and under inspection of the Animal Ethics
Committee of University of Tasmania, permit numbers A9491
and A11052. Captive devils were housed in groups of two or three
in 100 m
2 enclosures. Animals were fed possum or wallaby meat
once a day and water ad libitum. All procedures (blood collection,
skin graft surgery, biopsy and bandage removal) were performed
with the animals under general anaesthesia and all efforts were
made to minimise pain or discomfort.
Two-way mixed lymphocyte reaction
Fifteen Tasmanian devils from five areas in eastern Tasmania
(Nugent, Epping, Mount William National Park, Forestier
Peninsula and Bronte Park) and nine devils from four regions in
western Tasmania (Woolnorth, Temma, Granville Harbour and
Milkshake Hills) were used. Figure 1 shows a map of Tasmania
with the geographical locations of all devils used for MLR and skin
graft experiments. The DFTD-affected area is also illustrated.
Whole blood was collected into lithium heparin tubes from the
jugular vein while under general anaesthesia. Mononuclear cells
were harvested using density gradient centrifugation as described
previously [14]. Cells were diluted to a concentration of 10
6 cells/
mL in RPMI 1640 incomplete medium (CSL Limited 05182301)
supplemented with 10% pooled devil plasma, 2 mM of glutamine
(Sigma G7513) and 15 mg of gentamicin (Pfizer 61022010).
MLR experiments were conducted in U-bottomed 96 well
plates (Iwaki 3870-096), mixing 100 mL of a mononuclear cell
suspension from one devil with 100 mL of a mononuclear cell
suspension from another devil. Background controls consisted of
200 mL of mononuclear cells from individual devils incubated
alone and positive controls consisted of mononuclear cells of
individual devils incubated with 50 mg/mL of Concanavalin A
(Con A, Sigma C7275). Mixed lymphocyte cultures were
incubated at 37uC and 5% CO2 for 144 hours. Mitogen controls
were incubated under the same conditions for 96 hours. Eighteen
hours prior the harvesting, cultures were pulsed with 1 mCi
tritiated thymidine (Amersham Pharmacia Biotech TRA 310) to
assess proliferation. Cells were harvested onto a filter paper and
dried overnight at room temperature. Uptake of thymidine by
proliferating cells was measured by radiation emittance using a
scintillation counter (Pharmacia, 1214 Rackbeta). Results were
obtained in counts per minute (CPM) and stimulation indices (SI)
were calculated with the formula: SI=Average CPM of mixed
culture/Average CPM of control cultures. Mitogen stimulated
culture controls were calculated by dividing the average of
incorporated thymidine in stimulated cultures by non-stimulated
cultures. All SI controls were considered to be one in the MLR
experiments, as no proliferation was characterised in autologous
cultures. All experiments were conducted in triplicates. MLR
results were considered strong when SI .10, moderate when
Figure 1. Origin of Tasmanian devils used for mixed lympho-
cyte reactions and skin graft surgery. Mount William National Park,
Epping, Bronte Park, Nugent and Forestier Peninsula were considered
eastern sites, whereas Woolnorth, Temma, Milkshake Hills and Granville
Harbour were considered western sites. The grey area illustrates the
DFTD-affected area in 2010 (http://tinyurl.com/3b6d8qf). Number of
devils used in MLR experiments from each area is shown in brackets.
doi:10.1371/journal.pone.0022402.g001
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differences in MLR stimulation indices between groups and
between ‘eastern versus eastern’, ‘western versus western’ and
‘eastern versus western’, results were log transformed and analysed
with nonparametric Mann Whitney test with non-Gaussian
distribution.
Skin graft procedures
Seven unrelated captive devils of eastern Tasmania were used
for two-way skin grafting experiments (one of the animals was used
for two procedures). All devils were three year old females, except
TD 187, which was a three year old male. Table 1 shows the
pairing and origin of devils for each procedure. Surgeries were
performed in two devils simultaneously. Animals were pre-
medicated with acepromazine (0.2 mg/Kg) and morphine
(1 mg/Kg) injected subcutaneously. For further analgesia, xylo-
caine 1% was injected in the subcutaneous tissue around the
surgery site (not exceeding 20 mg/Kg). General anaesthesia was
induced by isofluorane delivered via an endotracheal tube. The
hair of the surgery site (the dorsal area of the animal) was clipped
and shaved and the site disinfected with a solution of chlorexidine
and cetrimide. The surgery field was covered with a sterile
fenestrated drape.
A square (368 cm) was drawn on the skin of the mid-dorsal
region of each devil and a dermatome knife with a sterile blade
was used to ‘shave’ 1 mm thick dermis and epidermis of the
demarcated skin. This loose piece of skin was divided into
approximately two equal pieces (approximately 364 cm) and one
of them slid in to the cranial wound (autograft). The other piece
(allograft) was placed in sterile Hartmann’s solution, until the same
procedure had been performed on the other devil. The allograft
skin pieces were then placed in the caudal position of the wound.
Surgical glue was placed on the borders of the grafts to secure the
skin. A sterile dressing was applied to the surgical wound and the
thoracic and chest areas were covered with cotton wool and elastic
bandages under firm pressure. Bandages were changed on Day 7
and removed on Day 14. Pain relief medication (meloxicam
0.05 mg/Kg) was administered in the food for three to five days
after skin graft surgery.
Monitoring of the grafts
On Days 7, 14 and 21 the grafts were visually inspected for signs
of rejection. The grafts were photographed and a punch biopsy (3–
4 mm) was taken from the grafts and fixed in 10% buffered
formalin solution for one to four weeks. After fixation, skin biopsy
punches were processed and paraffin embedded. Four to six
sections (3 mm thickness) were cut onto 3-aminotriethoxysilane
(Sigma A7222) coated slides for haematoxylin and eosin staining
and the same number of sections was prepared for immunohis-
tochemistry.
Immunohistochemistry
Skin biopsies were labelled for T-cells with a rabbit anti-human
CD3 antibody (Dako A0452). Isotype controls included non-
specific rabbit immunoglobulin fraction (Dako X0903) and
negative controls were labelled without the primary antibody
(replaced with antibody diluent, Dako S0809). Sections of devil
lymph nodes were used as positive controls.
Tissue sections were deparaffinised in xylene and rehydrated
through graded alcohol solutions to water and boiled in citrate
buffer solution (pH 6) in an electric pressure cooker for 10 minutes
at medium heat. Slides were left to cool to 35uC and placed in
PBS. Endogenous peroxidase activity was quenched by incubating
sections with a solution of 3% H2O2 for 15 minutes and non-
specific protein binding was blocked with serum-free protein block
solution (Dako X0909) for 30 minutes. The antibody was diluted
(1:800) with antibody diluent and placed onto the slides for 60
minutes. Antibody binding was detected by placing a biotinylated
link universal followed by streptavidin and horseradish peroxidase
(30 minutes each) (LSAB kit, Dako K0690). A solution of
diaminobenzidine (Dako K3466) was placed onto the slides for
ten minutes to allow for brown colour development of positive cells
and then washed with distilled water. Sections were briefly
counterstained with haematoxylin for 40 seconds, dehydrated
through graded alcohol solutions to xylene and coverslipped.
Histology and CD3-labelled sections were examined for signs of
immunological rejection and a pathological score adapted from a
previous study in human hand transplantation [30] was given to
each section. Table S1 describes the criteria used to determine
immune rejection.
Genotyping of skin graft recipients and donors
The seven individuals used for skin graft experiments were
genotyped at MHC I a chain and MHC II b chain loci through
nucleotide sequencing. Genomic DNA samples were extracted
from fresh or frozen whole blood using MoBio UltraClean
BloodSpin Kit. The a1 domain of MHC I genes and b1 domain of
MHC II genes were amplified by PCR using previously published
primers and PCR conditions [17,31]. PCR amplifications were
performed on a Bio-Rad MJ Mini Personal Thermal Cycler and
the Platinum Taq DNA Polymerase High Fidelity Kit (Invitrogen
11304-011) was used to ensure the lowest error rate. PCR products
were isolated by running 1.8% agarose TBE gels using Bioline
HyperLadder IV as size marker and purified from the gel using
UltraClean 15 DNA Purification Kit (MoBio 12100-300). Purified
DNA fragments were cloned in a pGEM-T Easy Vector (Promega
A1360) /JM109 High Efficiency Competent Cells (Promega
L1001) cloning system. Twenty-four clones were picked for each
sample. Plasmids were extracted using UltraClean 6 Minute Mini
Plasmid Prep Kit (MoBio 12300-250) and sequenced in two
directions with T7 and SP6 primers at the Australian Genome
Research Facility. Two independent PCRs were performed for
each individual, and only sequence variants found in more than
one PCR amplification were included in the subsequent analyses
to minimize nucleotide errors yielded during PCR, cloning and
sequencing. The sequencing results were quality-checked in
Sequencher 4.1.4 (Gene Codes) and aligned with previously
identified devil MHC alleles [17] in BioEdit using the ClustalW
alignment tool [32,33].
Results
Tasmanian devils respond in mixed lymphocyte reactions
To confirm that the mononuclear cell suspensions were able to
proliferate, all suspensions were incubated with the mitogen Con
Table 1. Origin and pairing of Tasmanian devils used for skin
graft experiments.
Tasmanian devil ID Origin
TD 190 and TD 199 Nugent and Epping
TD 187 and TD 200 Nugent and Mount William National
Park
TD 188 and TD 189 Forestier Peninsula and Nugent
TD 190 and TD 191 Nugent and Forestier Peninsula
doi:10.1371/journal.pone.0022402.t001
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experiment conditions were optimum (data not shown). There was
a wide range of MLR responses among all groups, from SI,1t o
SI.100. Figure 2a summarises the MLR proliferations among the
eastern groups. The MLRs from devils from Mount William
National Park showed the highest SI, whereas the MLRs from
devils from Nugent had the lowest responses. Figure 2b illustrates
the MLR responses among the western groups. The MLRs from
devils from Granville Harbour and Woolnorth had the highest
proliferations, whereas MLRs from devils from Milkshake Hills
and Temma had the lowest responses. Because DFTD is spreading
from eastern to western areas of Tasmania, we investigated the
functional MHC diversity between devils from these two areas.
Figure 2c shows that the MLR responses from west versus east
devils were significantly higher than the MLR responses from east
versus east devils and west versus west devils. In order to compare
these results more effectively, the SI was characterised as either
strong (SI.10), moderate (5,SI,10) or low or no reaction
(SI,5). Most MLRs between devils from east and west yielded
strong responses. Figure 3 illustrates the intensity of MLR
responses among all groups.
Tasmanian devils reject skin allografts
Skin graft surgeries were performed to test whether allogeneic
tissue from an unrelated devil would be immunologically accepted
by the recipient devil. Five of the eight skin allografts and six of the
eight autografts engrafted successfully, as determined by macro-
scopic and histological assessment. The remaining three allografts
and two autografts showed pathological changes characteristic of
mechanical trauma, resulting in failure of these tissues to engraft.
The main histological alterations in these unsuccessful grafts were
necrosis associated with polymorphonuclear cell infiltration,
surface parakeratosis and fibrin deposition.
All successful grafts appeared indistinguishable from the
autografts at Day 7. Four of five engrafted allografts had
macroscopic changes associated with immune rejection 14 days
following the surgery. These changes consisted of scaly lesions,
coagulative exudates and brown to black coloration of the
allografted skin. For one allograft, these macroscopic changes
were not visible until 17 days after the procedure. Microscopically,
immune rejection was characterised as Grade II, III or IV
rejection (moderate, severe or very severe, respectively). Typical
alterations were moderate to severe perivascular and interstitial
CD3 infiltration, dermal and epidermal lymphocytic exocytosis,
usually accompanied by apoptotic keratinocytes and epidermal
necrosis. Spongiosis was a common finding. Most of these
alterations were recognised 14 days after the surgery, and
progressed to very severe rejection on Day 21. In three cases,
there was total loss of the allografted skin, hence a biopsy could not
be taken. Table 2 summarises the results for all surgeries (Table S2
describes the pathological changes of the allografts in detail) and
Figure 4 shows the macroscopic and microscopic appearance of a
representative result from one experiment.
Figure 2. Mixed lymphocyte reaction between groups. Results are presented as stimulation indices and median is shown. Statistical
significance is illustrated as *p,0.05, **p,0.005 and ***p,0.0001. A. Mixed lymphocyte reactions within eastern groups. Devils from Mount William
National Park had the highest median proliferations, followed by devils from Forestier Peninsula. B. Mixed lymphocyte reactions within western
groups. Devils from Granville Harbour had the highest stimulation indices compared to the other groups. C. Mixed lymphocyte reactions between
eastern and western groups. Median stimulation indices were highest when experiments were conducted between eastern and western devils.
doi:10.1371/journal.pone.0022402.g002
Figure 3. Intensity of MLR responses among all groups. Intensity
of MLR responses varied greatly among devils. The greatest responses
occurred in MLR between devils from east and west Tasmania.
doi:10.1371/journal.pone.0022402.g003
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MHC genotyping and MLR results for animals used for the skin
graft surgeries are summarized in Table 3 and Table 4. TD 190
and TD 199 have exactly the same set of MHC I and II alleles.
TD 188 and TD 189 have three (two MHC I and one MHC II)
allelic mismatches, resulting in amino acid variations at two
peptide binding sites in MHC I a1 domain. The other two pairs of
individuals both have four MHC allele mismatches but no
different amino acid substitutions at peptide binding sites were
identified.
Discussion
The presence of a histocompatibility system should prevent the
establishment of transmissible cancers in vertebrates [34,35]. Despite
this, in addition to DFTD, two other naturally transmissible tumours
in mammals exist. Canine transmissible venereal tumour (CTVT)
[36], which affects members of the Canidae family. A transmissible
sarcoma in captive Syrian hamsters (Mesocrycetus auratus), which was
either artificially or spontaneously transmitted by social interactions
[37]. CTVT down-regulates MHC antigens [38] and secretes
Figure 4. Skin graft between unrelated Tasmanian devils. A–C: Macroscopic appearance of the autograft (arrowhead) and allograft (arrow), at
seven, 14 and 21 days after surgery. Dark dots in the grafts are scars from punch biopsies. D–F: Histological appearance of allografts at seven, 14 and
21 days after surgery, respectively. Note extensive mononuclear infiltration at 14 days after the surgery (E), and loss of epidermis at 21 days after
surgery (F). Scale bars represent 200 mm. G–I: CD3 labelling of allografts at seven, 14 and 21 days after surgery, respectively. Note the extensive CD3
infiltration at 14 days after surgery (H). Scale bars represent 200 mm.
doi:10.1371/journal.pone.0022402.g004
Table 2. Outcome of skin allografts.
Tasmanian devil ID Day 7 Day 14 Day 21
TD 190 Grade II Grade IV Necrotic skin, biopsy not done
TD 199 No evidence of rejection Grade III Grade IV
TD 187 Unable to determine rejection Grade IV Necrotic skin, biopsy not done
TD 188 No evidence of rejection Grade III Grade IV
TD 191 No evidence of rejection Grade III Necrotic skin, biopsy not done
TD 190 was the only devil that showed an early rejection response at Day 7. All five devils had Grade III to Grade IV rejection at Day 14 and Day 21.
doi:10.1371/journal.pone.0022402.t002
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Syrian hamsters bearing transmissible sarcomas originated from a
single family [40], suggesting that they were highly monomorphic at
the MHC loci. The mechanism of DFTD tumour acceptance is still
unclear. Low MHC variation between devils is the most accepted
hypothesis to explain the susceptibility of the species to this cancer
[16].
Even though Tasmanian devils lack MHC diversity [17], it is
becoming apparent that devils are capable of allogeneic responses.
Our previous work showed low MLR responses using pooled
lymphocytes as stimulators [16]. It is likely that different (or rare)
MHC antigens were ‘diluted out’ and not present in enough
quantity to stimulate proliferation of the responder cells. The
present experiments produced responses throughout the devil
range, although some MLR experiments yielded low or no
proliferations, suggesting that these devils share most MHC
antigens. Importantly, some high responses were identified in the
MHC-impoverished eastern population, in which DFTD has
spread rapidly. The greatest MLR responses were found between
eastern and western devils, which possess differences in the MHC
nucleotide sequence [17]. We confirmed this by sequencing MHC
I and II alleles from two western devils (data not shown). These
animals had three MHC I and two MHC II alleles that were not
present in the eastern population analysed. This indicates that
allelic and antigenic differences might be behind the higher
allogeneicity between the two populations. The MLR results
suggest that unaltered allogeneic cells should initiate an immune
response in most recipient devils, irrespective of the origin of the
animal.
All successful allografts were acutely rejected, despite low MLR
responses in three out of the four skin graft pairs and little or no
mismatches in MHC I and II alleles. The rejection of the foreign
tissue was usually visible macroscopically and microscopically by
14 days after the procedure. The grafts could only be assessed
every seven days, as procedures with live devils require general
anaesthesia. In this context, the onset of rejection occurred
between seven and 14 days, which is within the normal range (8–
12 days) [41,42]. The low MLR responses and the combined
MHC I and II genotyping would suggest that a slower rejection
should have occurred. This was not the case, suggesting that little
mismatches can activate an allogeneic response in devils. Indeed,
allografts in animal models may only require a single amino acid
difference between donor and recipient to be rejected [43,44]. In
addition, other genetic (such as cytokine genes and killer cell
immunoglobulin-like receptor haplotypes) and non-genetic (such
as age, source of skin and size of the graft) factors may also affect
the transplant outcome [45,46,47]. In human transplantation,
allografts from fully matched unrelated donors can still be rejected,
unless the recipient receives immunosuppressive therapy [48,49].
The advantage of using skin transplants is that the outcome of the
experiments is easily visualised. The disadvantage is that skin is a
very immunogenic tissue and might be rejected more rapidly than
other organs [42,50]. Skin harbours cells expressing MHC I and
II, plus minor histocompatibility complex molecules, all of which
can act as alloantigens and trigger rejection. Nonetheless, it is clear
that little antigenic or allelic mismatches are sufficient to trigger
rapid rejection of foreign tissue between unrelated devils.
The florid T-cell infiltration observed in the skin allografts
contrasts with the absence of tumour infiltrating lymphocytes in
DFTD tumours [4,8]. Down-regulation of the MHC machinery is
a well-known mechanism that tumour cells, including CTVT,
utilise to escape destruction by T-cells [38,51,52,53]. The
expression of MHC I and II proteins by DFTD tumour cells still
needs to be resolved. DFTD tumour cells express MHC I and II at
mRNA level [16], but it is unknown whether this is translated into
functional proteins. Preliminary experiments in our laboratory
Table 3. MHC genotyping of Tasmanian devils used for skin graft experiments.
Tasmanian devil ID MHC I a1 sequence variants MHC II b1 sequence variants
TD 190 SahaI*27, 28, 32, 35, 49 SahaDAB*01, 03, 05
TD 199 SahaI*27, 28, 32, 35, 49 SahaDAB*01, 03, 05
TD 187 SahaI*28, 32, 35, 49, 57 SahaDAB*01, 03, 05, 12
TD 200 SahaI*27, 28, 32, 35, 49 SahaDAB*01, 03, 05, 11
TD 188 SahaI*27, 32, 35, 49 SahaDAB*01, 03, 05, 15
TD 189 SahaI*27, 32, 35, 48 SahaDAB*01, 03, 05, 11, 15
TD 191 SahaI*28, 32, 34, 48, 49 SahaDAB*01, 03, 05, 13
TD 190 and TD 199 shared all MHC I and II alleles. The remaining devil pairs had two to three MHC I allelic mismatches and one to two MHC II allelic mismatches.
doi:10.1371/journal.pone.0022402.t003
Table 4. Amino acid difference count at peptide binding sites and MLR results within skin graft devil pairs.
Tasmanian devil ID
Amino acid difference count at
peptide binding sites at MHC I a1
Amino acid difference count at
peptide binding sites at MHC II b1 Mixed lymphocyte reaction (SI)
TD 190 and TD 199 0 0 1
TD 187 and TD 200 0 0 1
TD 188 and TD 189 2 0 17
TD 190 and TD 191 0 0 5
TD 188 and TD 189 had two amino acid differences at peptide binding sites at MHC I a1 and had a strong MLR response. The other three pairs did not have amino acid
difference count at peptide binding sites at MHC I a1 or MHC II b1 and had low MLR responses.
doi:10.1371/journal.pone.0022402.t004
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cell surface (unpublished data). It has not been possible to test for
MHC I expression, due to the lack of specific antibodies. In
tumours with changed MHC profile, NK cells are activated and
promote the killing of abnormal cells [54]. Although devils possess
the expected range of immune cells [55], NK cell function has still
to be explored in the Tasmanian devil. Tumours can utilise other
mechanisms to evade immune recognition. Increased resistance to
cytotoxic molecules, such as perforin [56], decreased tumour
antigen expression [57] and secretion of immunosuppressive
factors, such as IL-4, IL-10 and transforming growth factor-b1
[58,59] are alternative (or concurrent) mechanisms of immune
escape.
The devil population is under threat because an allogeneic
tumour cell clone is being transferred between animals without
immune recognition. The host is immunocompetent [14,15], but
the population has undergone bottlenecks in the past and lacks
genetic and MHC diversity [16,17,60]. This homogeneity in the
population, however, is not sufficient to allow allotransplantation
between unrelated devils. DFTD tumour cells are likely to have
evolved adaptive mechanisms to survive unhindered in the tissues
of the new host.
Supporting Information
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